Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.
Pharma & Biotech
Pharma & Biotech
Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.
Pharma & Biotech
Neurocrine Biosciences strengthens INGREZZA case with functional improvement data
Mild TD can still disrupt work and independence. Neurocrine’s INGREZZA data raises pressure to rethink when treatment begins.
Pharma & Biotech
Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.
Pharma & Biotech
Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Pharma & Biotech
Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?
GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.
Pharma & Biotech
Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?
EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.
Pharma & Biotech
How Full-Life Technologies is using US$150m to push beyond platform promise
Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.
Medical Devices & Diagnostics
Artivion’s Endospan acquisition puts NEXUS at the centre of aortic arch device competition
Artivion now owns NEXUS. The bigger test is whether FDA approval can become a scalable U.S. aortic arch business.
Medical Devices & Diagnostics
HistoSonics just cleared a major Asia hurdle. Could histotripsy move beyond liver tumors next?
HistoSonics cleared Taiwan, but the bigger test is whether histotripsy can scale from liver tumors into broader oncology use.